The difficulties industry is facing with investigators.

Area of Science:

• Oncology
• Pharmaceutical Science
• Clinical Research

Background:

• The past decade has seen a significant rise in novel anti-cancer agent development.
• This surge has intensified collaborations between the pharmaceutical industry and academic/clinical researchers.

Purpose of the Study:

• To identify key issues arising from industry-academia interactions in cancer drug development.
• To propose actionable solutions for optimizing these collaborations.

Main Methods:

• Qualitative analysis of industry-academia interactions.
• Identification of common challenges faced by both sectors.
• Development of proposed solutions based on identified issues.

Main Results:

• Several challenges were identified in the collaboration process.
• Specific areas of friction include intellectual property, data sharing, and regulatory hurdles.
• Proposed solutions aim to streamline processes and improve communication.

Conclusions:

• Addressing identified issues is crucial for efficient cancer drug development.
• Enhanced collaboration frameworks can accelerate the delivery of new cancer therapies to patients.
• Proactive problem-solving will benefit both pharmaceutical developers and clinical investigators.